Thalidomide in Combination With Capecitabine in Patients With Metastatic Breast Cancer

SCRI Development Innovations

Status and phase

Terminated

Phase 2

Conditions

Breast Cancer

Treatments

Drug: Thalidomide

Drug: Capecitabine

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT00193102

SCRI BRE 60

Details and patient eligibility

About

The lack of non-overlapping toxicities between the two drugs, the ease of all oral drug administration, and the possibility for antitumor synergy make exploration of this combination regimen attractive in women with previously treated metastatic breast cancer. This phase II trial will be performed in collaboration with the Minnie Pearl Cancer Research Network, a multicenter, community-based clinical trials group.

Full description

Upon determination of eligibility, patients will be receive:

Thalidomide + Capecitebine

Enrollment

40 estimated patients

Sex

Female

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

To be included in this study, you must meet the following criteria:

Metastatic breast cancer confirmed by biopsy
Measurable or evaluable disease
Females > 18 years
Able to perform activities of daily living with minimal assistance
Life expectancy > 3 months
Adequate bone marrow, liver and kidney function
All patients must give written informed consent in order to participate.

Exclusion criteria

You cannot participate in this study if any of the following apply to you:

Women who are pregnant or lactating.
Received more than 3 prior chemotherapy regimens in the metastatic setting.
Received continuous infusion 5-fluorouracil lasting > 120 hours.
Received thalidomide or capecitabine as their last prior regimen.
Preexisting moderate to severe neuropathy

Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.